# A Study of HS-20094 in Patients With T2DM

> **NCT06901648** · PHASE2 · COMPLETED · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 275 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** HS-20094
- **DRUG:** Dulaglutide
- **DRUG:** Palcebo

## Key facts

- **NCT ID:** NCT06901648
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-06
- **Primary completion:** 2025-03-07
- **Final completion:** 2025-04-09
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06901648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06901648, "A Study of HS-20094 in Patients With T2DM". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06901648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*